ReviewObesity (Silver Spring, Md.)2022
Metabolic dysfunction and obesity-related cancer: Beyond obesity and metabolic syndrome.
Review in Obesity (Silver Spring, Md.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07262593 (Family-Based Meal Timing for Cancer Prevention Among Native Hawaiian and Other Pacific Islanders), which is not on this map. Cited by 101 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Family-Based Meal Timing for Cancer Prevention Among Native Hawaiian and Other Pacific Islanders: FAMTIME
Who cites it
101 citing papers in PubMed, 8 syntheses or guidelines pooled it, 149 citations in OpenAlex.
- Metabolic Syndrome and Obesity-related cancer Risk and Survival: An Umbrella Review of Systematic Reviews With Meta-analysis of Observational Studies.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026Pooled it
- Bariatric Surgery and Remission of Metabolic Syndrome: A Meta-analysis of Randomised Controlled Trials and Prospective Studies.Obesity surgery · 2025Pooled it
- Correlation between Metabolic Syndrome and Gastric Cancer: Results of an Evidence-Based Strategy in Oriental Populations.Combinatorial chemistry & high throughput screening · 2025Pooled it
- Association of metabolic obesity phenotypes with risk of overall and site-specific cancers: a systematic review and meta-analysis of cohort studies.British journal of cancer · 2024Pooled it
- Dietary inflammatory index and its association with risk of metabolic syndrome and its components: a systematic review and Meta-analysis of Observational studies.Journal of health, population, and nutrition · 2024Pooled it
- The relationship between metabolic syndrome and survival of patients with endometrial cancer: a meta-analysis.Frontiers in oncology · 2024Pooled it
- Systematic Review and Meta-Analysis of the Impact of Bariatric Surgery on Future Cancer Risk.International journal of molecular sciences · 2023Pooled it
- Metabolic syndrome and survival of patients with hepatocellular carcinoma: A meta-analysis.Frontiers in oncology · 2023Pooled it
- Metainflammation, Mitochondrial Dysfunction, and Organokine Crosstalk: A Central Axis Linking Metabolic Syndrome to Cardiovascular Diseases.International journal of molecular sciences · 2026Review
- Identification of alpha1-oleate as a potent regulator of adipokine-dependent metabolism, in bladder cancer tissue.Cancer & metabolism · 2026Article
- Regional Trends and Forecasts of Pancreatic Cancer Incidence in Poland: A Voivodeship-Level Analysis of Risk Factors.Journal of clinical medicine · 2026Article
- Article
- Real-world obesity prevalence and history in 79 271 patients receiving systemic anticancer therapy across 13 cancer types in England (2013-2023).ESMO real world data and digital oncology · 2026Article
- Structured higher protein meal replacement plans for weight loss and metabolic health: A qualitative narrative evidence review of Medifast interventions.Obesity pillars · 2026Review
- A sweet danger: the silent link between hyperinsulinemia and gastric cancer.Molecular cancer · 2026Review
- Fueling or Fighting Cancer? The Thermogenic Paradox of Brown Adipose Tissue.Current obesity reports · 2026Review
- Metabolic permissiveness: how tissue context shapes cancer.Genes & development · 2026Review
- Rising trends in obesity and cancer-related mortality in the United States: a population-based analysis, 1999-2020.Journal of the Endocrine Society · 2026Article
- Cholesterol Promotes Lung Adenocarcinoma Brain Metastasis by Stabilizing EGFR Protein to Drive EMT, Metabolic Reprogramming, and Premetastatic Niche Formation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Selected Parameters Which Support the Laboratory Diagnosis of Cardiovascular-Kidney-Metabolic Syndrome in the Light of Current Guidelines: A Narrative Review.Journal of clinical medicine · 2026Review
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
Abstract
objectivesThe metabolic dysfunction driven by obesity, including hyperglycemia and dyslipidemia, increases risk for developing at least 13 cancer types. The concept of "metabolic dysfunction" is often defined by meeting various combinations of criteria for metabolic syndrome. However, the lack of a unified definition of metabolic dysfunction makes it difficult to compare findings across studies. This review summarizes 129 studies that evaluated variable definitions of metabolic dysfunction in relation to obesity-related cancer risk and mortality after a cancer diagnosis. Strategies for metabolic dysfunction management are also discussed.
methodsA comprehensive search of relevant publications in MEDLINE (PubMed) and Google Scholar with review of references was conducted.
resultsMetabolic dysfunction, defined as metabolic syndrome diagnosis or any number of metabolic syndrome criteria out of clinical range, inflammatory biomarkers, or markers of metabolic organ function, has been associated with risk for, and mortality from, colorectal, pancreatic, postmenopausal breast, and bladder cancers. Metabolic dysfunction associations with breast and colorectal cancer risk have been observed independently of BMI, with increased risk in individuals with metabolically unhealthy normal weight or overweight/obesity compared with metabolically healthy normal weight.
conclusionMetabolic dysfunction is a key risk factor for obesity-related cancer, regardless of obesity status. Nonetheless, a harmonized definition of metabolic dysfunction will further clarify the magnitude of the relationship across cancer types, enable better comparisons across studies, and further guide criteria for obesity-related cancer risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.